Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage

British Journal of Anaesthesia

Volumn 97, Issue 4, 2006, Pages 476-481

  Bowles, K M ^a   Callaghan, C J ^a   Taylor, A L ^a   Harris, R J ^a   Pettigrew, G J ^a   Baglin, T P ^a   Park, Gilbert R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Blood, coagulation; Blood, loss; Blood, transfusion; Intensive care

Indexed keywords

PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

ADOLESCENT; ADULT; AGED; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL DISCHARGE; HUMAN; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; POSTOPERATIVE HEMORRHAGE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; REVIEW; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION;

EID: 33748878377     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/ael205     Document Type: Article

References (26)

1. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-9
2. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-18
3. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111: 78-90
4. Von Depka M. NovoSeven: Mode of action and use in acquired haemophilia. Intensive Care Med 2002; 28 (Suppl 2): S222-7
5. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes. Transfusion 2005; 45: 1434-42
6. Mittal S, Watson HG. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol 2006; 133: 355-36
7. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-5
8. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777-85
9. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: A randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102: 269-75
10. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroenterology 2004; 127: 1123-30
11. Midathada MV, Mehta P, Waner M, Fink LM. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004; 121: 124-37
12. Aitken MG. Recombinant factor VIIa. Emerg Med Australas 2004; 16: 446-55
13. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64
14. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005; 33: 883-90
15. Clark AD, Gordon WC, Walker ID, Tait RC. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004; 86: 120-4
16. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48
17. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-800
18. Arts DG, de Keizer NF, Vroom MB, de Jonge E. Reliability and accuracy of Sequential Organ Failure Assessment (SOFA) scoring. Crit Care Med 2005; 33: 1988-93
19. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-8; discussion 8-9
20. Biss TT, Hanley JP. Recombinant activated factor VII (rFVIIa/ NovoSeven(R)) in intractable haemorrhage: Use of a clinical scoring system to predict outcome. Vox Sang 2006; 90: 45-52
21. Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935-44
22. Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus EC, Heemskerk JW, De Groot PG. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 3: 742-51
23. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41: 101-8
24. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15; discussion 15-8
25. Mohr AM, Holcomb JB, Dutton RP, Duranteau J. Recombinant activated factor VIIa and hemostasis in critical care: A focus on trauma. Crit Care 2005; 9 (Suppl 5): S37-42
26. Spahn DR, Tucci MA, Makris M. Is recombinant FVIIa the magic bullet in the treatment of major bleeding? Br J Anaesth 2005; 94: 553-5